We're so pleased that you'd like to order our KnowNowᵀᴹ Tests. At the moment we are running some pilots with a few key partners, before distributing our tests more widely.
Please fill in our form and our team will get back to you.
From our own studies with partners, we estimate that a clinical professional can administer one test every 3.5 to 4 minutes. This assumes that they collect saliva samples from individuals, set the KnowNowᵀᴹ Test devices aside to develop for 15 minutes, and collect samples from further individuals before reading the results from earlier tests.
The adjective "vatic" means "describing or predicting what will happen in the future," and derives directly from the Latin word vates, meaning "seer" or "prophet."
We chose this name as it speaks to our mission to make healthcare more proactive and empowering, through predictive screening for acute disease.
SARS-CoV-2 is able to spread from individuals who are pre-symptomatic or asymptomatic. As a result, testing and isolation based on symptoms alone will not be sufficient to stop the spread.
This narrative review of 16 clinical studies around the globe concludes that between 40-45% of those infected with SARS-CoV-2 never develop symptoms, and that these asymptomatic carriers can infect others for an extended period, perhaps longer than 14 days.
Regular community testing with a rapid antigen test like the KnowNowᵀᴹ Test to identify asymptomatic, but infectious, individuals offers one way to break the chain of transmission and enable the re-opening of societies.
KnowNowᵀᴹ Tests should be stored between 2 and 30 degrees celsius, which means it's fine to store it at room temperature in the UK's mild climate.
There's no need to store it inside a fridge, unless you're expecting extremely hot weather. If you do choose to refrigerate the test though, just make sure it comes to room temperature before using it.
The KnowNowᵀᴹ Test device should also be stored still sealed in its foil pouch. Once removed from the foil pouch, it should be used within one hour.
There have been questions raised around the sensitivity of rapid lateral flow antigen testing for SARS-CoV-2 as compared to PCR testing. However, these questions have been strongly challenged by the scientific community.
PCR tests identify the presence of the SARS-CoV-2 virus in the body, regardless of whether the virus is actively infectious. The PCR testing process amplifies the genetic code of the virus so that even minuscule amounts of the virus in the sample can be picked up. This makes for a powerful test, but since viral fragments can linger in the body for weeks even after the infection has cleared, infected individuals being tested using PCR will show as positive for a median period of 22–33 days in total. On the other hand, most people infected with SARS-CoV-2 are contagious only for 4–8 days.
So whilst PCR testing for SARS-CoV-2 may have been considered the "gold standard" test up until now, it will by definition show different results when compared to lateral flow tests which aim to identify individuals based on viral loads which suggest they are within their infectious window. This discrepancy between what each test is actually testing for has caused some issues where PCR testing has been used to evaluate the effectiveness of lateral flow tests, such as in the mass testing rolled out in Liverpool in November 2020.
The KnowNowᵀᴹ Test goes a step beyond other lateral flow tests with its unique, patented detection mechanism which only shows a positive result when live infectious virus is identified in the sample. As a result, PCR tests will similarly show different results to the KnowNowᵀᴹ Test in certain cases, since they will show positive results even for individuals outside of their infectious period.
For a much more comprehensive and referenced answer, you may like to read "Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19" from the Lancet.
The KnowNowᵀᴹ test's unique detection mechanism identifies the infectiousness of the people tested. As a result, from our modelling based on accepted and peer-reviewed scientific literature, the KnowNowᵀᴹ test will detect asymptomatic people who are infectious with COVID-19.
The KnowNowᵀᴹ test has an impressively low limit of detection for an on-the-spot equipment-less test, of between 50,000 and 200,000 viral copies per mL, and so it is sensitive enough to identify infectious asymptomatic carriers even if they have low viral loads.
As the KnowNowᵀᴹ Test makes testing quicker, easier and more accessible, more people can get tested on an ongoing basis. Regular testing improves the chances of picking up asymptomatic carriers. Since the KnowNowᵀᴹ Test can detect the virus on day 3 to 4 after infection, based on KnowNow's low limit of detection and accepted models of viral load in disease progression, it identifies these carriers before they’re at a high risk of infecting other people.
Testing to identify asymptomatic carriers is so important, since they make up a large proportion of people who are infectious and enable the virus to keep spreading. This narrative review of 16 clinical studies around the globe concludes that between 40-45% of those infected with SARS-CoV-2 never develop symptoms, and that these asymptomatic carriers can infect others for an extended period, perhaps longer than 14 days.
Receiving a negative result means that the individual tested does not have any live virus in the sample provided and is not currently infectious to others. However, it's important to be aware that they could still be exposed to the SARS-CoV-2 virus following the test. It could also be possible that the individual tested has already been exposed to the virus 1 or 2 days ago, and they have not yet become infectious to others.
As a result, we recommend that individuals are tested as regularly as possible to keep workplaces and communities safe. Depending on the scenario, we would recommend testing is repeated every 1 to 3 days.
One box contains 25 tests, and measures 20cm (L) x 21cm (W) x 8cm (H).
The space required depends on how many tests you require at any given time. However, as the KnowNowᵀᴹ Tests can be stored at any temperature between 2 and 30 degrees, special storage facilities should not be required in the UK, unless there is unusually hot weather.
So that we adhere to the strict rules around lateral flow tests, we have to make sure that anyone activating a sample pack is doing so purely to learn more about KnowNow Testing, and not as means of administering a clinical test.
We chose to design our unique KnowNowᵀᴹ test for COVID-19 infectiousness to work with a simple saliva sample, so that it would be comfortable and easy to administer, and to ensure that anyone would be happy to take a test every day if required. We believe that patient comfort and happiness leads to increased participation in routine testing, and ultimately increases the probability that COVID positive patients can be detected before they've had a chance to infect others.
The focus of our first clinical study was to assess the feasibility of using saliva sampling, to refine our saliva collection method, and also to assess the overall usability of the KnowNow test. This was a UK Government-supported National Institute for Health Research (NIHR) study carried out across ten UK hospitals with 100 patients participating. Through this study we determined that saliva sampling was both effective and user-friendly, and identified a specific swab for sampling. We chose not to opt for a spit collection method for our saliva sample, as providing a spit sample can be challenging for some patients, particularly the elderly or those suffering with COVID-19 symptoms.
For other COVID-19 tests, throat and nasopharyngeal swabbing is one of the most common types of sample collection. However, a number of studies have explored various issues with these types of sample collection, including:
Some tests have been designed to work with anterior nasal swabs, as a somewhat less invasive alternative to nasopharyngeal swabs. However, there is some evidence to suggest that nasal swab testing produces less sensitive results and may miss patients with lower viral loads (4).